June 28, 2019
Video
Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Bringing Hope and Healing to Patients With Cancer
Discussing the Importance of Genetic Counseling in Women’s Cancer
Addressing Barriers to Care, Improving Access in Women’s Cancers
Transitioning from Active Care to Survivorship in Women’s Cancer